FR2891460B1 - Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum. - Google Patents

Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.

Info

Publication number
FR2891460B1
FR2891460B1 FR0510025A FR0510025A FR2891460B1 FR 2891460 B1 FR2891460 B1 FR 2891460B1 FR 0510025 A FR0510025 A FR 0510025A FR 0510025 A FR0510025 A FR 0510025A FR 2891460 B1 FR2891460 B1 FR 2891460B1
Authority
FR
France
Prior art keywords
compound
treatment
ophthalmic diseases
diseases due
demodex folliculorum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0510025A
Other languages
English (en)
Other versions
FR2891460A1 (fr
Inventor
Alexandre Kaoukhov
Christophe Villard
Philippe Bouissou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0510025A priority Critical patent/FR2891460B1/fr
Application filed by Galderma SA filed Critical Galderma SA
Priority to EP06842320.1A priority patent/EP1933849B1/fr
Priority to RU2008117148/15A priority patent/RU2008117148A/ru
Priority to CA002620814A priority patent/CA2620814A1/fr
Priority to CNA2006800354419A priority patent/CN101272796A/zh
Priority to PCT/IB2006/003864 priority patent/WO2007054822A2/fr
Priority to KR1020087006637A priority patent/KR20080053303A/ko
Priority to ARP060104302A priority patent/AR056553A1/es
Priority to AU2006313447A priority patent/AU2006313447A1/en
Priority to JP2008532906A priority patent/JP2009510049A/ja
Priority to EP12152476.3A priority patent/EP2455085B1/fr
Priority to BRPI0617537-6A priority patent/BRPI0617537A2/pt
Publication of FR2891460A1 publication Critical patent/FR2891460A1/fr
Priority to US12/059,086 priority patent/US20090093421A1/en
Application granted granted Critical
Publication of FR2891460B1 publication Critical patent/FR2891460B1/fr
Priority to US13/160,408 priority patent/US8361974B2/en
Priority to US13/716,667 priority patent/US8987218B2/en
Priority to US14/284,524 priority patent/US9457038B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
FR0510025A 2005-09-30 2005-09-30 Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum. Expired - Fee Related FR2891460B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0510025A FR2891460B1 (fr) 2005-09-30 2005-09-30 Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
EP12152476.3A EP2455085B1 (fr) 2005-09-30 2006-09-29 Utilisation topique par application dans l'oeil de l'ivermectine, pour le traitement des pathologies ophtalmiques
CA002620814A CA2620814A1 (fr) 2005-09-30 2006-09-29 Utilisation d'au moins un compose de la famille des avermectines ou des milbemycines pour le traitement de pathologies ophtalmiques
CNA2006800354419A CN101272796A (zh) 2005-09-30 2006-09-29 至少一种阿弗菌素或米尔倍霉素在治疗眼科疾病中的用途
PCT/IB2006/003864 WO2007054822A2 (fr) 2005-09-30 2006-09-29 Utilisation d'au moins un compose de la famille des avermectines ou des milbemycines pour le traitement de pathologies ophtalmiques
KR1020087006637A KR20080053303A (ko) 2005-09-30 2006-09-29 안과 병리 치료에서 하나 이상의 아버멕틴 또는밀베마이신의 용도
ARP060104302A AR056553A1 (es) 2005-09-30 2006-09-29 Utilizacion de al menos un compuesto de la familia de las avermectinas o de la familia de las milbemicinas para el tratamiento de las patologias oftalmicas
AU2006313447A AU2006313447A1 (en) 2005-09-30 2006-09-29 Use of at least one avermectin or milbemycin in the treatment of ophthalmic pathologies
EP06842320.1A EP1933849B1 (fr) 2005-09-30 2006-09-29 Utilisation d'ivermectine pour le traitement des pathologies ophtalmiques
RU2008117148/15A RU2008117148A (ru) 2005-09-30 2006-09-29 Применение, по меньшей мере, одного соединения из семейства авермектинов или из семейства милбемицинов для лечения глазных патологий
BRPI0617537-6A BRPI0617537A2 (pt) 2005-09-30 2006-09-29 uso de pelo menos um composto da famÍlia das avermectinas
JP2008532906A JP2009510049A (ja) 2005-09-30 2006-09-29 眼科症状の治療における、アベルメクチンファミリーまたはミルベマイシンファミリーの少なくとも１つの化合物の使用
US12/059,086 US20090093421A1 (en) 2005-09-30 2008-03-31 Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies
US13/160,408 US8361974B2 (en) 2005-09-30 2011-06-14 Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies
US13/716,667 US8987218B2 (en) 2005-09-30 2012-12-17 Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies
US14/284,524 US9457038B2 (en) 2005-09-30 2014-05-22 Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510025A FR2891460B1 (fr) 2005-09-30 2005-09-30 Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.

Publications (2)

Publication Number Publication Date
FR2891460A1 FR2891460A1 (fr) 2007-04-06
FR2891460B1 true FR2891460B1 (fr) 2010-07-30

Family

ID=35840100

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0510025A Expired - Fee Related FR2891460B1 (fr) 2005-09-30 2005-09-30 Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.

Country Status (5)

Country Link
US (4) US20090093421A1 (fr)
EP (1) EP2455085B1 (fr)
CN (1) CN101272796A (fr)
BR (1) BRPI0617537A2 (fr)
FR (1) FR2891460B1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR2947453B1 (fr) * 2009-07-03 2011-08-19 Akil Sa Medicament antiparasitaire pour application topique contre les affections dues au demodex
WO2012092320A2 (fr) 2010-12-29 2012-07-05 Nichamin Louis D Traitement oculaire
CN102600195A (zh) * 2012-03-21 2012-07-25 华南农业大学 一种宠物用复方透皮搽剂及其制备方法和应用
AU2014356444B2 (en) 2013-11-29 2019-11-21 Galderma Holding SA Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
WO2016022066A1 (fr) * 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
AU2017305853B2 (en) * 2016-08-04 2023-04-13 Galderma Holding SA Compositions and the use thereof for treating or preventing rosacea
NZ766141A (en) 2017-12-15 2024-01-26 Tarsus Pharmaceuticals Inc Isoxazoline parasiticide formulations and methods for treating blepharitis
KR20210061336A (ko) 2018-07-27 2021-05-27 아페르타 바이오사이언시스 엘엘씨 모낭충으로 유발된 안구 및 안면 증상의 치료를 위한 스피노신 제제
KR20210113975A (ko) * 2018-10-12 2021-09-17 호비온 사이언티아 리미티드 마크로사이클릭 락톤 제제, 이의 제조방법, 및 안과 기생충에 대한 이차적인 병리를 치료하는데 있어서의 상기 제제의 용도
CN114269324A (zh) * 2019-06-19 2022-04-01 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US20210052490A1 (en) * 2019-08-20 2021-02-25 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
EP4247367A1 (fr) 2020-11-23 2023-09-27 Sight Sciences, Inc. Formulations et procédés de traitement d'affections de l'?il
CN114504550B (zh) * 2022-04-18 2022-08-19 中山大学中山眼科中心 一种包含甲硝唑的眼用凝胶及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614545A (en) * 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
WO2002089743A2 (fr) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Compositions pour le traitement de l'acne rosacee
US8273366B2 (en) * 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
US20040228921A1 (en) * 2003-02-14 2004-11-18 Chowdhury Dipak K. Compositions and methods for delivery of therapeutic agents

Also Published As

Publication number Publication date
US20120053140A1 (en) 2012-03-01
US20140256662A1 (en) 2014-09-11
US20130109642A1 (en) 2013-05-02
CN101272796A (zh) 2008-09-24
US9457038B2 (en) 2016-10-04
FR2891460A1 (fr) 2007-04-06
US8987218B2 (en) 2015-03-24
EP2455085B1 (fr) 2017-05-10
EP2455085A2 (fr) 2012-05-23
US20090093421A1 (en) 2009-04-09
BRPI0617537A2 (pt) 2011-07-26
US8361974B2 (en) 2013-01-29
EP2455085A3 (fr) 2012-07-18

Similar Documents

Publication Publication Date Title
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
FR13C0029I1 (fr) Compositions pour le traitement de troubles gastro-intestinaux
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
WO2004080423A3 (fr) Composes de 7-amino- isoindolyle et leurs utilisations pharmaceutiques
WO2004075823A8 (fr) Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
WO2009069032A3 (fr) Nouveaux agonistes des récepteurs des glucocorticoïdes
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
FR2890306B1 (fr) Dispositif pour le traitement d'une poche vasculaire
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
MA29097B1 (fr) Composes pour le traitement des infections virales par flaviviridae
WO2008098985A3 (fr) Composition pharmaceutique pour le traitement de maladies à médiation par il-8
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
FR2896422B1 (fr) Systeme de drainage pour le traitement de l'hydrocephalie
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
FR2884716B1 (fr) Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20200914